- Land: Deutschland
Nachricht vom 22.05.2019 | 17:56
Notification of Stabilization Measures in accordance with Article 5 (4) and (6) of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ('Market Abuse Regulation')
DGAP-News: Joh. Berenberg, Gossler & Co. KG / Key word(s): Miscellaneous
NOT FOR DISTRIBUTION OR PUBLICATION IN THE UNITED STATES, CANADA, AUSTRALIA, OR JAPAN.
Notification of Stabilization Measures in accordance with Article 5(4) and (6) of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ("Market Abuse Regulation") of 16 April 2014 and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and in accordance with Article 6(1) of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016.
Joh. Berenberg, Gossler & Co. KG ("Berenberg" or the "Stabilization Manager"), in connection with the initial public offering of ABACUS MEDICINE A/S, Copenhagen, Denmark (the "Company") and with regard to the Company's shares, which are expected to be admitted to trading on the regulated market of the Frankfurt Stock Exchange (Prime Standard) on 29 May 2019 (International Securities Identification Number (ISIN: DK0061111739; German Securities Code (WKN): A2N6X0), has assumed the position as Stabilization Manager and will have the right, in the time period beginning on the date of the commencement of trading and ending 30 calendar days thereafter, i.e., (presumably) 31 May 2019 through and including 30 June 2019 (the "Stabilization Period"), in the scope admissible under Article 5(4) of the Market Abuse Regulation, to make Over-Allotments (as defined below) or carry out Stabilization Measures (the "Stabilization Measures").
Stabilization Measures are intended to provide support for the stock exchange or market price of the Company's securities during the Stabilization Period if the securities come under selling pressure, thus alleviating sales pressure generated by short-term investors and maintaining an orderly market in those securities. Stabilization Measures may cause the stock exchange or market price of the shares to be higher than it would otherwise have been. In addition, the stock exchange or market price may temporarily be at a level that is not sustainable. In addition, stabilisation activities may give false or misleading signals regarding the supply of the securities. The Stabilization Manager may carry out Stabilization Measures at the regulated market of the Frankfurt Stock Exchange. The Stabilization Manager is not required to carry out Stabilization Measures. Therefore, no assurance can be provided that Stabilization Measures will be carried out. As a result, Stabilization Measures may not necessarily be carried out and any Stabilization Measures may cease at any time without advance notice.
In any Stabilization Measures that may be carried out, and to the extent permitted by law, up to 645,930 additional shares may be alloted to investors as part of the offering in addition to the initial offer of shares in the Company (the "Over-Allotment"). In connection with a potential Over-Allotment, the Stabilization Manager has been provided with up to 645,930 shares from the holdings of the selling majority shareholder by way of a securities loan granted free of charge, and this number of shares equals 15% of the initial offering.
In this context, with the sole purpose of covering potential Over-Allotments, the selling majority shareholder has granted the Stabilization Manager an option to acquire up to 645,930 shares from the holdings of the selling majority shareholder (the "Greenshoe Shares") at the offer price less agreed commissions, thus satisfying the retransfer obligation under the securities loan (the "Greenshoe Option"). The Stabilization Manager may exercise the Greenshoe Option on one or more occasions. The Greenshoe Option will expire 30 calendar days after stock exchange trading in the shares commences and may only be exercised to the extent shares have been placed by way of Over-Allotment.
During the Stabilization Period, the Stabilization Manager ensures adequate public disclosure of the details of any Stabilization Measures by the end of the seventh day of trading following the date on which Stabilization Measures were carried out. The Stabilization Manager will also ensure that any exercise of the Greenshoe Option will be disclosed to the public, together with all appropriate details.
Within one week of the end of the Stabilization Period, adequate public disclosure of the following information will be made: whether or not Stabilization Measures were carried out; the dates on which any price Stabilization Measures started and ended; the date on which Stabilization Measures last occurred; the price range within which Stabilization Measures were carried out (for each date of a Stabilization Measure); and the trading venues on which Stabilization Measures (if any) were carried out.
This communication constitutes neither an offer to sell nor a solicitation to buy securities. The public offering (in Germany) will be made solely by means of, and on the basis of, a published securities prospectus. An investment decision regarding the publicly offered securities of ABACUS MEDICINE A/S should only be made on the basis of the securities prospectus. The securities prospectus which has been approved by the Danish Financial Supervisory Authority (Finanstilsynet) and notified to the Bundesanstalt für Finanzdiensleistungsaufsicht (BaFin) has been published on the Company's website www.abacusmedicine.com under the "Investor Relations" section and will be available free of charge at the Hamburg office of the Stabilization Manager.
This communication is not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This communication does not constitute or form part of an offer of securities for sale or solicitation of an offer to purchase securities in the United States, Canada, Australia, Japan, or in any other jurisdiction in which such offer may be restricted. The securities referred to in this communication have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from the registration requirements under the Securities Act. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares in the United States. There will be no public offering of securities in the United States or anywhere else, except for Germany.
In the United Kingdom, this communication is directed only at persons who: (i) are qualified investors within the meaning of the Financial Services and Markets Act 2000 (as amended) and any relevant implementing measures and/or (ii) are outside the United Kingdom or (iii) have professional experience in matters relating to investments and fall within the definition of "investment professionals" contained in article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or are persons falling within article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or fall within another exemption to the Order (all such persons referred to in (i) to (iii) above together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
Notification of Stabilization Measures in acco ...
Notification of Stabilization Measures in acco ...
The Carlyle Group Intends To Place Shares in K ...
Private placement of ordinary bearer shares in ...
Increase of sale of ordinary bearer shares in ...
Anleihe im Fokus
VST BUILDING TECHNOLOGIES AG: 7,00%-Anleihe 2019/2024 kann ab heute gezeichnet werden.
Emissionsvolumen der 5-jährigen Anleihe bis zu 15 Mio. Euro, Zeichnungsfrist vom 11.06.-25.06.2019
- WKN/ ISIN: A2R1SR / DE000A2R1SR7
- Stückelung: 1.000 Euro
- Kupon: 7,00 Prozent p.a. bei halbjährlicher Zinszahlung
- Zeichnungsfrist über Zeichnungsfunktionalität Börse Frankfurt voraussichtlich: 11 Juni 2019 bis 25 Juni 2019 (14:00 Uhr MESZ)
- Laufzeit: 28. Juni 2019 bis einschließlich 27. Juni 2024
- Rückzahlung: 28. Juni 2024
- Zinstermin: Halbjährlich
Interview im Fokus
„Schnelleres Wachstum mit Wasserstoff“
Mit dem Einstieg in die Wasserstoff-Technologie erschließt sich SFC Energy ein besonders dynamisches Segment. „Mittelfristig ist das Marktvolumen für Wasserstoff-Brennstoffzellen noch größer als im Direkt-Methanol-Bereich. Zivile Massenanwendungen könnten sich dabei zu einem echten Wachstumsbooster entwickeln“, ist CEO Dr. Peter Podesser überzeugt. Im Financial.de-Interview spricht der SFC-Vorstandschef u. a. über die aktuelle Euphorie für Brennstoffzellen-Aktien, die geplante Kapitalmaßnahme und das mittelfristige Umsatzziel von 100 Mio. Euro.
Studie GBC Best of m:access I.2019: Weiter im Aufwind und mit starker Outperformance
Das Qualitätssegment m:access hat sich in den letzten Jahren fulminant entwickelt und ist auch 2018 weiter gewachsen. Zuletzt umfasste der m:access einen Rekordwert von 60 Unternehmen unterschiedlichster Branchen mit einer Gesamtmarktkapitalisierung von rund EUR 12 Mrd. Der von GBC berechnete m:access Index hat im Betrachtungszeitraum eine starke Outperformance gezeigt. Auch für die neue Top 15 Best-Of-Auswahl sind die Analysten wieder sehr positiv gestimmt. Die Studie steht kostenlos zum Download zur Verfügung.
Der AKTIONÄR News
21. Juni 20:07 Alibaba: 3 Gründe, warum Kritiker vor der Aktie warnen
21. Juni 17:21 Fuchs Petrolub: Schmierstoff ohne Ende
21. Juni 15:58 Gazprom: Neues zur Dividende
News im Fokus
Linde Signs Long-Term Agreement with ExxonMobil to Supply Integrated Manufacturing Complex in Singapore
25. Juni 2019, 13:00
The BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
25. Juni 2019
Original-Research: Valneva SA (von First Berlin Equity Research GmbH): Kaufen Valneva SA
25. Juni 2019